Key Takeaways RFIL has been witnessing enormous recent price gains as U.S. markets begin 2026 in positive territory.BWMX jumped 32.7% in four weeks, backed by a 44.4% expected earnings growth rate for the current year.KRYS shares rose 10.5% in four weeks as Vyjuvek uptake and EU and Japan approvals support sales growth. U.S. stock markets have started 2026 on a positive note. All three major stock indexes are trading in positive territory. The fourth-quarter 2025 earnings season has been projected to remain ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

Core Insights - Krystal Biotech, Inc. (NASDAQ:KRYS) is recognized as a strong buy growth stock by hedge funds, with Citi raising its price target to $336 from $320 while maintaining a Buy rating [1] - The company announced preliminary unaudited financial results for fiscal Q4 and full year 2025, projecting VYJUVEK net product revenue between $106 million and $107 million for Q4 and between $388 million and $389 million for the full year [2] - As of December 31, 2025, Krystal Biotech reported cash, cash equivalents, and investments totaling approximately $955 million [2] Financial Performance - For fiscal Q4 2025, the expected net product revenue for VYJUVEK is projected to be between $106 million and $107 million [2] - The anticipated net revenue for the full year 2025 is expected to be in the range of $388 million to $389 million [2] - The preliminary unaudited results are based on initial management analysis and are subject to adjustment, with full financial results to be reported in February 2026 [3] Company Overview - Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing pharmaceutical products, including VYJUVEK, a topical gel for treating wounds in patients with dystrophic epidermolysis bullosa (DEB) [4]

Core Insights - The article discusses the 11 best strong buy growth stocks recommended by hedge funds, highlighting insights from Cathie Wood, CEO and CIO of Ark Invest, regarding market trends and inflation outlook [1][4]. Market Trends and Inflation - Cathie Wood noted that inflation is decreasing but remains reflected in reported numbers, leading to concerns about potential market corrections due to high valuations [2]. - Historical comparisons indicate that strong markets can occur even as valuation multiples decline, suggesting a need for caution in future valuations [2]. - Wood expressed optimism about inflation trends, attributing it to falling oil and housing prices, as well as productivity gains, with unit labor costs showing a year-over-year increase of 1.2% but negative in the last reported quarter [3]. Hedge Fund Stock Selection Methodology - The article outlines the methodology used to identify the top 11 stocks, focusing on those with the highest number of hedge fund holders as of Q3 2025, sourced from Insider Monkey's database [6]. - The selection criteria included EPS diluted growth above 20% year-over-year and a strong buy consensus rating from analysts [8]. Company Highlights - **Krystal Biotech, Inc. (NASDAQ:KRYS)**: - Number of hedge fund holders: 26 - Citi raised the price target from $320 to $336, maintaining a buy rating after the company announced preliminary unaudited financial results for 2025, expecting VYJUVEK net product revenue between $106 million and $107 million for Q4 2025 and $388 million to $389 million for the full year [9][10]. - The company reported cash and investments of approximately $955 million as of December 31, 2025 [10]. - **Sportradar Group AG (NASDAQ:SRAD)**: - Number of hedge fund holders: 31 - Wells Fargo reduced the price target from $30 to $26 while maintaining an overweight rating, citing a conservative approach to future estimates [13]. - Truist Financial reiterated a buy rating with a price target of $20.35, while Citizens adjusted the price target from $36 to $34, maintaining an outperform rating [14]. - The company operates in the sports betting and entertainment sector, providing various products and services [16].

Group 1 - Brendan, a Pennsylvanian, completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups including Theravance and Aspira before joining Caltech [1] - Brendan is the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured major investments in the 8 figures [1] - He remains an avid investor focused on market trends, particularly in biotechnology stocks [1]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Insights - Krystal Biotech, Inc. (KRYS) anticipates preliminary unaudited net product revenues of $106-$107 million from its lead drug Vyjuvek in Q4 2025, raising the full-year 2025 revenue forecast to $388-$389 million, driven by strong uptake in the U.S. and successful launches in Europe and Japan [1][11] Financial Performance - At the end of 2025, Krystal reported approximately $955 million in cash, cash equivalents, and investments, providing substantial financial flexibility for clinical programs [2] - For 2026, the company expects combined non-GAAP R&D and SG&A expenses to be between $175-$195 million [2] Pipeline Development - Krystal is advancing several rare disease programs utilizing its redosable HSV-1 gene therapy platform, targeting high-turnover tissues such as skin, lung, and eye [3] - Key pipeline candidates include KB803 for ocular complications of DEB, KB801 for neurotrophic keratitis, KB407 for cystic fibrosis, and KB111 for Hailey-Hailey disease [3] Clinical Trials and Updates - Enrollment in the registrational KB801 study has increased to 60 patients, indicating potential for expedited development, with a detailed update expected in February 2026 [4] - Top-line data from the KB801 and KB803 registrational studies are anticipated in 2026, serving as important near-term catalysts [6] - Other targets for 2026 include initiating and completing enrollment in a registrational repeat dose study for KB407 and starting a double-blind, placebo-controlled study for KB111 [7] Vyjuvek Developments - Vyjuvek received FDA approval in May 2023 as the first revocable gene therapy for treating patients aged six months or older with dystrophic epidermolysis bullosa (DEB) [8] - In September 2025, a label update expanded the treatment-eligible population to include DEB patients from birth and allowed for greater dosing flexibility [9][12] Long-term Strategy - The company aims to have at least four marketed rare disease therapies by 2030, targeting over 10,000 patients globally while maintaining profitability [5] - Krystal continues to invest in earlier-stage programs for larger indications, including KB408 for alpha-1 antitrypsin deficiency and KB707 for non-small cell lung cancer, which could provide long-term growth potential [5] Stock Performance - Shares of KRYS increased by 5% on January 9, with a notable 73.9% rise over the past year compared to the industry growth of 19.6% [16]

Core Viewpoint - The presentation focuses on the strategic vision and objectives of Krystal Biotech for the next five years, highlighting the recent launch of VYJUVEK for treating dystrophic epidermolysis bullosa [3][5]. Group 1: Company Overview - Krystal Biotech is led by CEO and Chairman Krish Krishnan and President of R&D Suma Krishnan, who are presenting at a healthcare investment banking conference [2]. - The presentation is structured into two parts: a strategic overview by the CEO and specific deliverables by the President of R&D [3]. Group 2: Product Launch - VYJUVEK was launched in September 2023, aimed at treating patients with dystrophic epidermolysis bullosa, showcasing its differentiated nature in the market [5].

PresentationBefore we begin, let me just outline a few logistics. During the presentations, the presenters will be on screen. [Operator Instructions]. And with that, I'll now hand over to Paul Hanratty.Good afternoon, ladies and gentlemen. My name is [indiscernible], and I am here of Investor Relations. Thank you all for joining us on this call.Paul HanrattyGroup CEO & Executive Director Thank you very much, and good afternoon, ladies and gentlemen. Thank you very much for joining us on this call. Can I sta ...

Summary of Krystal Biotech Conference Call Company Overview - **Company**: Krystal Biotech - **Industry**: Biotechnology, specifically focused on genetic medicines and rare diseases Key Points and Arguments Product Launch and Performance - **Vyjuvek**: Launched in September 2023 for treating Dystrophic Epidermolysis Bullosa (DEB) - First re-dosable genetic medicine and can be applied at home, which is a significant differentiation in gene therapy [3][4] - Positive patient and physician experiences reported, leading to high compliance and reimbursement approvals [4][6] - Launched in Europe (France, Germany) and Japan, with plans for further expansion in Europe [5][34] Financial Position - Krystal Biotech has achieved nearly 10 consecutive quarters of positive EPS since the launch of Vyjuvek [6] - Strong balance sheet with no immediate plans for financing, indicating financial stability [6][9] Manufacturing and Control - Two manufacturing facilities established to maintain control over critical manufacturing processes (CMC) [6][8] - Focus on in-house operations for packaging and supply chain management [8][9] Pipeline and Future Goals - Ambition to market four rare disease products by 2026, leveraging the success of Vyjuvek [9][10] - Pipeline includes: - **KB803**: Targets lesions in the eye of DEB patients, with a market potential of over $4 billion [12][14] - **KB801**: For neurotrophic keratitis, aiming for a more consistent delivery method compared to existing treatments [22][24] - **407**: For cystic fibrosis, showing promising data for delivering functional CFTR to patients [25][26] - **KB111**: For Hailey-Hailey disease, with plans for a registrational trial [27][30] Regulatory and Clinical Development - Ongoing registrational studies for KB803 and KB801, with expectations to complete enrollment by the end of the year [21][24] - Emphasis on patient-reported outcomes and innovative trial designs to enhance data collection and analysis [21][29] Market Strategy - Krystal Biotech aims to self-launch products in the U.S., EU, and Japan for rare diseases, while considering partnerships for larger indications [10][39] - The company is actively working on distribution agreements for countries where self-launch is not feasible [5][34] Insights from Global Launch - The launch of Vyjuvek has provided valuable insights into pricing and reimbursement strategies across different markets [15][34] - The company is learning from the global launch experience to refine its pipeline and market approach [15][34] Additional Important Information - The company has no royalty obligations to universities or pharmaceutical companies, allowing complete ownership of its pipeline [9] - The focus on rare diseases is driven by the company's capabilities in developing and commercializing such products [10][11] - The management team emphasizes the importance of CMC in gene therapy development, highlighting the need for robust manufacturing processes [31][32] This summary encapsulates the key points discussed during the conference call, focusing on Krystal Biotech's product launches, financial health, pipeline ambitions, and strategic market approaches.